http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103169946-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fe9b72f923ad55c646de947a240acebd |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 |
| filingDate | 2011-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3afc23e72a62ed88e08f8b24e0be6cc5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eec2e4ae096553192ace02204752e9f3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae55dd02e830422bf4d695852c5312fe |
| publicationDate | 2014-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103169946-B |
| titleOfInvention | Application of Safenour cyclopeptide in oral insulin medicine for treating diabetes |
| abstract | The invention discloses an application of Safenour cyclopeptide in an oral insulin medicine for treating diabetes, which comprises the following steps: 1) Safenour cyclopeptide and insulin are combined to have a protection effect; 2) after combining Safenour with insulin, the anti gastrointestinal tract acidic environment and digestive enzyme such as pepsin and trypsin after oral administration of insulin can be degraded; 3) absorption of intestinal tract on insulin can be promoted after combining Safenour with insulin; and 4) the administration is carried out after combining Safenour with insulin, the Safenour cyclopeptide has obvious diabetes and hpyerglycemic treatment effect. The security is high, the Safenour preparation is simple, and the problems that oral administration of insulin is easily degraded, so that unable oral administration and inconvenient carrying are provided can be solved. The oral insulin preparation which takes Safenour as an auxiliary material is easily carried, the usage is convenient, the problems of instability of natural insulin and quick-acting insulin analogues under acidic environment, twice injection on morning and evening everyday can be solved, and the Safenour cyclopeptide can be used for treating diabetes, and has good hpyerglycemic effect. The anti gastrointestinal tract degradating effect of the oral administration of insulin is good, and the Safenour cyclopeptide enables large scale production. |
| priorityDate | 2011-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 315.